← Back to Clinical Trials
Recruiting Phase 4 NCT05215132

NCT05215132 Investigational MRI Clinical Software and Hardware

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05215132
Status Recruiting
Phase Phase 4
Sponsor Northwestern University
Condition Image, Body
Study Type INTERVENTIONAL
Enrollment 2,000 participants
Start Date 2019-12-19
Primary Completion 2028-01-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
MRIGadavist 2Ml Solution for Injection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 2,000 participants in total. It began in 2019-12-19 with a primary completion date of 2028-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patients and healthy volunteers will be scanned in order to test new sequences.

Eligibility Criteria

Inclusion Criteria: * • At least 18 years of age * Able to complete the MR safety questionnaire. * Able to comprehend and provide informed consent in English. * When contrast is being administered: healthy volunteers with a GFR≥60 ml/min * When contrast is being administered: patients with a GFR ≥30 ml/min Exclusion Criteria: * • When contrast is being administered: subjects with a GFR \< 30 ml/min * When contrast is being administered: subjects with acute kidney injury * When contrast is administered, allergy to gadolinium-containing contrast media * Contraindication to MRI (implanted device, claustrophobia, dyspnea precluding the ability to follow breath-hold instructions) * Adults unable to consent * Individuals who are not yet adults * Pregnant or breastfeeding women * Prisoners

Contact & Investigator

Central Contact

Emily Powell

✉ emily.powell@northwestern.edu

📞 312.695.2956

Frequently Asked Questions

Who can join the NCT05215132 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Image, Body. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT05215132 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT05215132 currently recruiting?

Yes, NCT05215132 is actively recruiting participants. Contact the research team at emily.powell@northwestern.edu for enrollment information.

Where is the NCT05215132 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT05215132 clinical trial?

NCT05215132 is sponsored by Northwestern University. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology